J. D. Smeijer

Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease

D. Webb, D. Kohan, N. Dhaun, 2021, Current opinion in nephrology and hypertension.

Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.

J. McMurray, H. Parving, G. Bakris, 2022, JACC. Heart failure.

Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long‐Term Response to Atrasentan in Patients With Diabetic Kidney Disease

J. McMurray, H. Parving, G. Bakris, 2022, Clinical pharmacology and therapeutics.

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease

D. Zeeuw, R. Correa-Rotter, J. D. Smeijer, 2023, Cardiovascular Diabetology.

Post-hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.

D. de Zeeuw, R. Gansevoort, D. Kohan, 2023, Kidney international.

Endothelin receptor antagonists in chronic kidney disease.

J. D. Smeijer, Adrian Liew, Hiddo J. L. Heerspink, 2024, Nature reviews. Nephrology.